Europe's New Fast Lane for Breakthrough AI Devices Comes With No Governance Shortcut

A Second Fast Lane

In December 2025, the European Commission’s Medical Device Coordination Group published MDCG 2025-9, introducing a Breakthrough Devices framework under the Medical Devices Regulation (EU) 2017/745 and the In Vitro Diagnostic Regulation (EU) 2017/746. For AI device sponsors who have spent years treating the FDA’s own breakthrough pathway as the primary route to accelerated review, this changes the calculus. Europe now offers a comparable mechanism, and regulatory affairs teams have to decide, market by market, where to file first.

That decision matters more for AI-enabled devices than for traditional hardware. Consider ThinkSono Guidance, the AI-enabled ultrasound guidance software that recently cleared FDA’s 510(k) pathway for DVT evaluation. That clearance took the conventional route. A sponsor with a similarly novel imaging or diagnostic AI tool now has an actual choice between the established US predicate-based process and a new EU expedited designation, and the two pathways carry different evidence expectations, different timelines, and different post-market obligations.

Speed Is Not a Substitute for Governance

The temptation with any breakthrough designation is to treat acceleration as license to under-invest in governance infrastructure. That temptation is misplaced. As Medical Device Network’s analysis of AI imaging governance notes, the FDA has kept issuing draft guidance on AI device and software evaluation even under a White House executive order explicitly aimed at minimizing regulatory friction for AI innovators. Regulators on both sides of the Atlantic are converging on the same underlying expectation: faster review does not mean lighter documentation, weaker model validation, or thinner post-market surveillance.

For sponsors weighing the EU breakthrough route, that means MDR and IVDR quality management obligations, EU AI Act high-risk classification requirements for medical AI, and ongoing clinical evidence generation all remain in force regardless of designation status. Breakthrough status shortens the clock on review. It does not shorten the list of things a sponsor must prove.

The Decision

Companies developing AI-enabled diagnostic or imaging devices now face a genuine strategic fork rather than a single well-worn path. The EU breakthrough framework is new enough that its practical operation, including how strictly MDCG applies eligibility criteria and how much evidentiary flexibility it grants in practice, is still being tested. Sponsors should not assume symmetry with FDA’s program simply because the label is similar.

The prudent move is to build AI governance documentation, ISO 42001 alignment, and model lifecycle controls that satisfy the more demanding of the two regimes, then let the market entry sequencing follow from commercial priorities rather than governance shortcuts. A device that qualifies for expedited review in one jurisdiction but cannot produce the underlying evidence trail when a second regulator asks has not actually saved any time. It has just deferred the cost of proof to a later, less forgiving stage of the product’s life.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The central argument—that expedited review pathways don’t reduce governance obligations—is coherent and defensible, but the piece asserts regulatory convergence between FDA and EU without demonstratin
Source & Claim Verification	Qwen · local	cleared. All factual claims are traced to citations, but some sources are redundant and could be consolidated for clarity.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects core governance expectations under ISO 42001, EU AI Act, and MDR/IVDR but does not explicitly detail compliance requirements for each framework.
Technical Accuracy	Llama	cleared. The article accurately describes the European Commission’s Breakthrough Devices framework and its implications for AI-enabled medical devices, with proper citations and no technical inaccuracies.
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively anticipates and counters potential vendor hype by emphasizing that expedited review does not equate to relaxed governance or evidence requirements.
Novelty & Non-Duplication	Grok	held. Core peg is a restatement of the already-published Jones Day/MDCG 2025-9 alert, paired with an evergreen ‘breakthrough ≠ lighter governance’ thesis that is not differentiated from existing FDA/AI-Act
Validation	DeepSeek	cleared. The briefing’s core claim—that the EU’s new breakthrough pathway accelerates review but does not relax governance requirements—is validated by the cited regulatory sources, which emphasize the continu

Sources cited: 11. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.